CALGARY — November 3, 2025 — BiotechReporter.news
Hemostemix (TSXV:HEM) is staging a comeback in Canada’s biotech sector, announcing the completion of patient enrollment in its Phase 2 clinical trial for critical limb ischemia (CLI) and securing C$3 million in new financing to advance its pipeline.
The Calgary-based company specializes in autologous stem cell therapies for ischemic diseases. Its lead candidate, ACP-01, uses a patient’s own stem cells to regenerate blood vessels and restore circulation in affected limbs—a potential breakthrough for patients with limited surgical options.
The milestone marks a turning point for Hemostemix, which has faced operational and financial headwinds in recent years. Shares rose sharply following the announcement, reversing a prolonged downtrend and reigniting investor interest in the speculative small-cap.
“This is a pivotal moment for Hemostemix,” said CEO Thomas Smeenk. “We’ve overcome operational hurdles and are now focused on delivering clinical data that could transform treatment for vascular disease.”
The company’s C$3 million private placement, closed in October, provides runway for trial completion and regulatory engagement. The financing also supports broader strategic goals, including potential licensing deals and partnerships.
Hemostemix has streamlined its operations and resolved legacy intellectual property disputes, positioning itself for renewed visibility in the regenerative medicine space. With a clear clinical path and fresh capital, the company is re-entering the conversation as one of Canada’s more intriguing biotech rebound stories.
